key: cord-0782591-tqjql6bj authors: Patel, Shikha; Saxena, Bhagawati; Mehta, Priti title: Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19 date: 2021-01-29 journal: Heliyon DOI: 10.1016/j.heliyon.2021.e06158 sha: 7398c53d252d8076a44095abed40759efa4cfd5e doc_id: 782591 cord_uid: tqjql6bj Clinical studies have identified a cytokine storm in the third stage of disease progression in critical ill patients with coronavirus disease 2019 (COVID-19). Hence, effectively suppressing the uncontrolled immune response of the host towards the invaded viruses in a cytokine storm is a critical step to prevent the deterioration of patient conditions and decrease the rate of mortality. Therapeutic monoclonal antibodies (mAbs) are found to be effective for the management of acute respiratory distress syndrome in patients with COVID-19. In this review, we compiled all therapeutic mAbs targeting cytokine storm, which are in clinical trials for its repurposing in the management of COVID-19. Compilation of clinical trial data indicated that therapeutic monoclonal antibodies targeting interleukins (IL-6, IL-1ra, IL-8, IL-1β, IL-17A, IL-33), interferon-gamma, tumor necrosis factor-alpha, P-selectin, connective tissue growth factor, plasma kallikrein, tumor necrosis factor superfamily 14, granulocyte macrophage colony stimulating factor, colony stimulating factor 1 receptor, C-C chemokine receptor type 5, cluster of differentiation 14 and 147, vascular endothelial growth factor, programmed cell death protein-1, Angiopoietin - 2, human factor XIIa, complementary protein 5, natural killer cell receptor G2A, human epidermal growth factor receptor 2, immunoglobulin-like transcript 7 receptor, complement component fragment 5a receptor and viral attachment to the human cell were under investigation for management of severely ill patients with COVID-19. Among these, about 65 clinical trials are targeting IL-6 inhibition as the most promising one and Tocilizumab, an IL-6 inhibitor is considered to be the potential candidate to treat cytokine storm associated with the COVID-19. Data regarding the correlation between COVID-19 and cytokine storm are still limited. However, reports of clinical findings in a patient affected with SARS CoV-2 revealed that pro-inflammatory cytokines such as IL-1β, IL-2, IL-4, IL-6, IL-7, IL-8, IL-9, IL-10, IFN-γ, GM-CSF, TNF-α are significantly elevated . Clinical studies show that the levels of IL-6 are significantly elevated in the complicated cases of COVID-19 and highly correlated with clinical outcomes (Coomes and Haghbayan, 2020). Several biological agents like convalescent plasma, neutralize antibodies, mAbs, IFNs aiming towards inflammatory cytokines and cytokines receptors have been preferred for the management of ARDS in patients as potential candidates. They alleviate the effects of cytokines released in response to the COVID-19 and reduce lung damage in severely ill patients. Several studies have trailed strategies to dampen inflammatory responses. We would like to focus on the significance of therapeutic mAbs targeting cytokine storm in the management of COVID-19 based on ongoing clinical trials. Data were collected from the website of Clinical trials.gov up to 9 September 2020 and analysed for the number of mAbs under clinical trials. The mAbs are classified as per their biological targets and further scrutinized as per the registered phase of clinical trials to identify the most druggable biological target and potential candidate to treat COVID-19 related cytokine storm. A total of 125 clinical trials are registered for the repurposing of mAbs in the management of ARDS in COVID-19 infected patients spread throughout the world but the majority of trials trials targeting various cytokines IL-6, IL-1ra, IL-8, IL-1β, IL-17A, IL-33, IFN-γ, TNF-α, P-selectin, connective tissue growth factor (CTGF), plasma kallikrein, tumor necrosis factor superfamily (TNFSF)14, GM-CSF, colony stimulating factor 1 receptor (CSF-1R) , C-C chemokine receptor type 5 (CCR5), cluster of differentiation (CD) 14 and 147, VEGF, programmed cell death protein-1 (PD-1), angiopoietin -2, human factor XIIa, complementary protein 5, natural killer cell receptor G2A (NKG2A), human epidermal growth factor receptor 2 (HER2), immunoglobulin-like transcript 7 (ILT7) receptor, complement component fragment 5a receptor (C5aR) and viral attachment to the human cell ( Figure 5 and Table 2 ). However, the majority of mAb that are under clinical trials are IL-6 inhibitors for healing patients with moderate and severe COVID-19 (Figure-5 ). There are seven candidates that target IL-6 (tocilizumab, sarilumab, siltuximab, sirukumab, clazakizumab, olokizumab, levilimab). Among these maximum clinical studies are undergoing on tocilizumab among all the mAbs candidates as well as mAbs targeting IL-6 ( Figure 4 and Figure 6 ). Therefore, tocilizumab is considered to be the most promising candidate for management of cytochrome storm in COVID-19. It is evident that augmented levels of IL-6 were observed in patients infected with SARS-CoV-2 and correlated with disease severity ( Clazakizumab is an investigational humanised monoclonal antibody against IL-6, which is also considered a potential candidate for the management of cytochrome strom associated with COVID- Although not yet FDA approved, It is primarily registered for phase II clinical trials for the Olocizumab is also an investigational monoclonal antibody against IL-6. Tocilizumab and sarilumab are under evaluation in phase IV clinical trials, and siltuximab is in phase III for COVID-19 patients. Apart from that canakinumab (monoclonal antibody against human IL-1β), anakinra (recombinant human IL-1R antagonist), and emapalumab (monoclonal antibody against human IFN-γ) are promising mAbs to treat the cytokine storm associated with severe forms of COVID-19. Phase-III is futurized to be considered as the most promising therapeutic strategy amongst all as it is able to thwart SARS-CoV-2 at the initial phase only by targeting the spike protein on its surface (Renn et al., 2020). Therapeutic monoclonal antibodies are also exploring targets other than cytokines for the prevention and treatment of COVID-19. (tocilizumab, sarilumab, siltuximab, sirukumab, clazakizumab, olokizumab, levilimab). Among these maximum clinical studies on tocilizumab. Therefore, tocilizumab is considered to be the most promising candidate for management of cytochrome storm in COVID-19. Cytokine Responses in Severe Acute Respiratory Syndrome Coronavirus-Infected Macrophages In Vitro: Possible Relevance to Pathogenesis Cytokine storm and sepsis disease pathogenesis Cytokine storm and sepsis disease pathogenesis Tocilizumab -A beacon of hope in 81 Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) Tocilizumab in the treatment of a critical COVID-19 patient: A case report Elevated levels of IL-10 and G-CSF associated with asymptomatic malaria in pregnant women Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19) USA Available Not mentioned Monalizumab Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection France Suspended Phase-2